Mouse Monoclonal RASSF2 Antibody

+ +

•  

   
     Anti-RASSF2 Antibody at 1:2000 dilution + Raji whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 38 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Overlay histogram showing Raji cells stained with P33588(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P33588,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OJ192088) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG2a (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

The Ras association domain-containing protein 2 (RASSF2) is a member of the RASSF tumor suppressor family, which plays critical roles in regulating apoptosis, cell cycle arrest, and epigenetic modulation. Located on chromosome 20p13. RASSF2 contains a Ras-association (RA) domain and a Salvador/RASSF/Hippo (SARAH) domain, enabling interactions with Ras-related GTPases and components of the Hippo signaling pathway (e.g., MST1/2). It is frequently epigenetically silenced via promoter hypermethylation in various cancers, including colorectal, gastric, and lung cancers, correlating with poor prognosis and tumor progression.

RASSF2 antibodies are essential tools for studying its expression, localization, and functional mechanisms. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect RASSF2 in cell lines, tissues, or preclinical models. Specific clones are validated for cross-reactivity, species specificity (e.g., human, mouse), and application compatibility. Researchers utilize these antibodies to explore RASSF2's tumor-suppressive roles, such as its involvement in inhibiting Wnt/β-catenin signaling or promoting pro-apoptotic pathways. Additionally, they help identify RASSF2's methylation status as a potential biomarker for cancer diagnosis or therapy response. Commercial RASSF2 antibodies are typically raised against epitopes within the N-terminal or C-terminal regions, with validation data confirming target specificity via knockout controls or siRNA knockdown. Understanding RASSF2's interplay with oncogenic pathways through antibody-based assays remains vital for advancing cancer research and therapeutic strategies.